Kymera Therapeutics, Inc. 8K

Kymera Therapeutics reported Q2 2026 results, accelerated timelines for key STAT6 and IRF5 degrader programs, recognized major collaboration milestones from Sanofi and Gilead, announced new leadership appointments, and confirmed a strong cash runway into 2029.

On August 5, 2026, Kymera Therapeutics, Inc. reported its second quarter 2026 financial results and provided a comprehensive business update, highlighting accelerated enrollment completion in its KT-621 BROADEN2 Phase 2b atopic dermatitis trial with topline data now expected by year-end 2026 and Phase 3 initiation targeted by mid-2027, ongoing KT-621 Phase 2b asthma and KT-579 Phase 1 programs, the commencement of a Phase 1 trial for partnered IRAK4 degrader KT-485 by Sanofi that triggered a $20 million milestone, Gilead’s exercise of its option to exclusively license CDK2 degrader KT-200 resulting in a $45 million payment, strengthened leadership appointments including a new Chairman and Chief Medical Officer, and a solid liquidity position of approximately $1.5 billion in cash and investments as of June 30, 2026 providing runway into 2029 despite a quarterly net loss of $61.2 million.

Filing Facts

CIK

1815442

Ticker

KYMR

Form

8K

Source Type

fda

Accession

0001193125-26-333834

Alert Tier

6